Where data were available, in several of our sex-specific sensitivity analyses we found evidence for a causal effect where little evidence was seen in the primary analysis (for instance, we found evidence for an effect of female-specific but not sex-combined fasting insulin on risk of luminal B/HER2-negative-like breast cancer risk). This evidence concerns the gene ERBB2 and breast carcinoma.